CL2012000913A1 - Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. - Google Patents

Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.

Info

Publication number
CL2012000913A1
CL2012000913A1 CL2012000913A CL2012000913A CL2012000913A1 CL 2012000913 A1 CL2012000913 A1 CL 2012000913A1 CL 2012000913 A CL2012000913 A CL 2012000913A CL 2012000913 A CL2012000913 A CL 2012000913A CL 2012000913 A1 CL2012000913 A1 CL 2012000913A1
Authority
CL
Chile
Prior art keywords
advanced
morpholinthieno
iodophenylamino
azetidin
methanone
Prior art date
Application number
CL2012000913A
Other languages
English (en)
Inventor
Marcia Belvin
Iris T Chan
Lori Friedman
Klaus Hoeflich
John Prescott
Jaffrey Walin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000913(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012000913A1 publication Critical patent/CL2012000913A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Método de tratamiento para tumores sólidos localmente avanzados o metastásicos que consiste en administrar una combinación farmacéutica que contiene un compuesto de fórmula I o II y un compuesto de fórmula III.
CL2012000913A 2009-10-12 2012-04-11 Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico. CL2012000913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12

Publications (1)

Publication Number Publication Date
CL2012000913A1 true CL2012000913A1 (es) 2012-09-14

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000913A CL2012000913A1 (es) 2009-10-12 2012-04-11 Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.

Country Status (24)

Country Link
US (1) US20110086837A1 (es)
EP (1) EP2488178B1 (es)
JP (2) JP2013507415A (es)
KR (1) KR101489045B1 (es)
CN (1) CN102740851B (es)
AR (1) AR078588A1 (es)
AU (1) AU2010314287A1 (es)
BR (1) BR112012008483A2 (es)
CA (1) CA2776944A1 (es)
CL (1) CL2012000913A1 (es)
CO (1) CO6531463A2 (es)
CR (1) CR20120173A (es)
EC (1) ECSP12011865A (es)
ES (1) ES2609767T3 (es)
IL (1) IL219105A0 (es)
MA (1) MA33974B1 (es)
MX (1) MX345155B (es)
NZ (1) NZ599939A (es)
PE (1) PE20121816A1 (es)
PH (1) PH12012500709A1 (es)
RU (1) RU2563193C2 (es)
TW (1) TWI428336B (es)
WO (1) WO2011054620A1 (es)
ZA (1) ZA201202618B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2849331A1 (en) 2011-10-13 2013-04-18 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria
PE20142312A1 (es) * 2011-10-28 2015-01-25 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
AU2013243429A1 (en) * 2012-04-06 2014-10-23 Merck Patent Gmbh Methods for treating cancer using PI3K inhibitor and MEK inhibitor
EP2851078B1 (en) * 2012-04-19 2017-06-07 Kyushu University, National University Corporation Pharmaceutical composition
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2879665A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
JP2016515132A (ja) * 2013-03-14 2016-05-26 ジェネンテック， インコーポレイテッド Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (es) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
CA2186947A1 (en) * 1994-04-01 1995-10-12 Kazuo Ueda Oxime derivative and bactericide containing the same as active ingredients
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Also Published As

Publication number Publication date
BR112012008483A2 (pt) 2019-09-24
CO6531463A2 (es) 2012-09-28
CA2776944A1 (en) 2011-05-12
JP5745678B2 (ja) 2015-07-08
WO2011054620A1 (en) 2011-05-12
AR078588A1 (es) 2011-11-16
CN102740851A (zh) 2012-10-17
ES2609767T3 (es) 2017-04-24
AU2010314287A1 (en) 2012-05-03
PE20121816A1 (es) 2013-01-02
EP2488178A1 (en) 2012-08-22
PH12012500709A1 (en) 2012-10-29
KR101489045B1 (ko) 2015-02-02
AU2010314287A2 (en) 2012-07-12
KR20120064132A (ko) 2012-06-18
JP2013507415A (ja) 2013-03-04
ECSP12011865A (es) 2012-06-29
CR20120173A (es) 2012-07-04
TWI428336B (zh) 2014-03-01
TW201118082A (en) 2011-06-01
CN102740851B (zh) 2013-12-18
RU2012118974A (ru) 2013-11-20
MX345155B (es) 2017-01-18
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
MA33974B1 (fr) 2013-02-01
US20110086837A1 (en) 2011-04-14
IL219105A0 (en) 2012-06-28
NZ599939A (en) 2014-02-28
HK1175125A1 (en) 2013-06-28
JP2015038110A (ja) 2015-02-26
ZA201202618B (en) 2014-10-29
EP2488178B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
CL2012000913A1 (es) Uso de una combinacion farmaceutica de compuestos especificos derivados de 4-morfolintieno[3,2-d]pirimidina con 3,4-difluoro-2-(2-fluoro-4-iodofenilamino)fenil)(3-hidroxi-3-((2s)piperidin-2-il)azetidin-1-il)metanona para tratar localmente un tumor solido avanzado o metastasico.
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
GEP20125469B (en) Inhibitors of akt activity
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
JO2848B1 (en) Organic compounds
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
CY1115902T1 (el) Συνδυαστικη θεραπεια καρκινου με ανασταλτικες ενωσεις hps90
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA200970486A1 (ru) Соединения для ингибирования митоза
MY183014A (en) Compounds for enzyme inhibition
TW200738725A (en) Unsaturated mTOR inhibitors
TN2011000053A1 (en) Organic compounds
GEP20146060B (en) Pyridyl inhibitors of hedgehog signalling
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
TN2011000291A1 (en) Purine compounds
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
ECSP12012140A (es) Compuestos de para la inhibición de inmunoproteasomas
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
PH12012501813A1 (en) Iap bir domain binding compounds